Figure 1.
Survival analyses. (A) Progression-free survival (PFS) and (B) overall survival (OS) for the entire population and the subset of patients who received EA consolidation; PFS was defined as the time from diagnosis until progression, relapse from CR, or death. OS was defined as the time from diagnosis until death from any cause. PFS and OS were evaluated using the Kaplan-Meier method. EA: etoposide and cytarabine.